Junshi Biotech: Junshi Biotech 2024 Annual Performance Report Announcement

SZSIFeb 27 11:00 ET · Announcements

Junshi Biotech 2024 Annual Results Report Announcement

SZSIFeb 27 11:00 ET · Announcements

JUNSHI BIO: INSIDE INFORMATION -2024 PRELIMINARY RESULTS

HKEXFeb 27 05:58 ET · Announcements

JUNSHI BIO (688180.SH): Net loss of 1.28 billion yuan in 2024.

On February 27, Gelonghui reported that JUNSHI BIO (688180.SH) announced its 2024 annual performance preliminary report, with total revenue of 1,948.3173 million yuan, an increase of 29.67% year-on-year, and a net income attributable to the parent company's owners of -1,282.2792 million yuan. During the reporting period, the company's revenue increased mainly due to the sales revenue of commercialized Pharmaceuticals compared to the same period last year. By the end of the reporting period, the company had already owned Trepulimab injection (trade name: Tuoyi), Adalimumab injection (trade name: Junmaikang), Dextromethorphan hydrobromide tablets (trade name: Mindewei), and Angorin.

Gelonghui FinanceFeb 27 03:34 ET

Express News | Junshi Biosciences Prelim 2024 Net Loss at 1.3 Bln Yuan

ReutersFeb 27 03:30 ET

Orient: The market prospects for lipid-lowering drugs are broad, with new targets and new technological routes continually being validated.

Due to the rising incidence of dyslipidemia, which is increasingly affecting younger populations, the market for lipid-lowering drugs has a broad outlook. At the same time, new targets and new technological routes are being continuously validated, and the approval of Innovative Drugs can also drive rapid market expansion.

Zhitong FinanceFeb 12 01:00 ET